Abalos Therapeutics GmbH has appointed Gerben Moolhuizen as chief executive officer as the company advances its lead programme ABX-001 towards clinical evaluation in solid tumours. Mr Moolhuizen brings over three decades’ experience in drug development, business development and technologies in the biopharmaceutical industry. He was previously CEO and chief business officer at ISA Pharmaceuticals, general manager at OctoPlus and held business development roles at Pharming Group. Mr Moolhuizen holds an MSc in medical biology from Utrecht University and an MBA from Erasmus University Rotterdam, both in the Netherlands. Abalos is planning its first in-human trial for ABX-001 in 2025. The company’s arenavirus-based drug candidates are designed to trigger innate and adaptive immune responses from within the tumour.
Abalos Therapeutics announced the appointment on 9 October 2024.
Copyright 2024 Evernow Publishing Ltd